Paulina Tegethoff, Robert Perneczky, Marleen Taute, Amy Deckert, Michael Hornbecker, Sophia Rutt, Anna Hufnagel, Soeren Mattke, Carolin Kurz
{"title":"Motivation, Worries and Digital Affinity in Cognitive Screening - Qualitative Findings From the CogScreen Study.","authors":"Paulina Tegethoff, Robert Perneczky, Marleen Taute, Amy Deckert, Michael Hornbecker, Sophia Rutt, Anna Hufnagel, Soeren Mattke, Carolin Kurz","doi":"10.1177/08919887261429558","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Subjective cognitive decline is considered one of the earliest signs of Alzheimer's disease (AD), making early detection crucial for disease-modifying treatments to have the greatest impact. The CogScreen study, supported by the Davos Alzheimer's Collaborative Healthcare System Preparedness Program, evaluates tools for community-based screening of AD in its early stages. This study investigates subjective experiences, focusing on motivations, concerns, and potential improvements regarding digital tools used in cognitive assessments.<b>Methods:</b> Semi-structured qualitative interviews were conducted with a random selection of 28 participants with subjective cognitive decline or healthy controls. Interviews were transcribed and analyzed using conventional content analysis (MAXQDA, VERBI Software, 2024). <b>Results:</b> Analysis identified emergent themes related to the usability of digital tools, the importance of clear communication, and the desire for a more personalized research experience. Participants highlighted motivations and concerns regarding the implementation of digital assessments. <b>Discussion:</b> Findings support the feasibility of integrating digital assessments in aging populations and underscore the importance of addressing participants' motivations, concerns, and digital affinity when introducing innovative tools into clinical practice. <b>Conclusion:</b> Insights from this study contribute to future participant engagement strategies and the development of early detection methods for cognitive impairment. <b>Trial Registration:</b> CogScreen is registered at ClinicalTrials.gov (NCT06191952).</p>","PeriodicalId":16028,"journal":{"name":"Journal of Geriatric Psychiatry and Neurology","volume":" ","pages":"8919887261429558"},"PeriodicalIF":2.8000,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Geriatric Psychiatry and Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08919887261429558","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Subjective cognitive decline is considered one of the earliest signs of Alzheimer's disease (AD), making early detection crucial for disease-modifying treatments to have the greatest impact. The CogScreen study, supported by the Davos Alzheimer's Collaborative Healthcare System Preparedness Program, evaluates tools for community-based screening of AD in its early stages. This study investigates subjective experiences, focusing on motivations, concerns, and potential improvements regarding digital tools used in cognitive assessments.Methods: Semi-structured qualitative interviews were conducted with a random selection of 28 participants with subjective cognitive decline or healthy controls. Interviews were transcribed and analyzed using conventional content analysis (MAXQDA, VERBI Software, 2024). Results: Analysis identified emergent themes related to the usability of digital tools, the importance of clear communication, and the desire for a more personalized research experience. Participants highlighted motivations and concerns regarding the implementation of digital assessments. Discussion: Findings support the feasibility of integrating digital assessments in aging populations and underscore the importance of addressing participants' motivations, concerns, and digital affinity when introducing innovative tools into clinical practice. Conclusion: Insights from this study contribute to future participant engagement strategies and the development of early detection methods for cognitive impairment. Trial Registration: CogScreen is registered at ClinicalTrials.gov (NCT06191952).
期刊介绍:
Journal of Geriatric Psychiatry and Neurology (JGP) brings together original research, clinical reviews, and timely case reports on neuropsychiatric care of aging patients, including age-related biologic, neurologic, and psychiatric illnesses; psychosocial problems; forensic issues; and family care. The journal offers the latest peer-reviewed information on cognitive, mood, anxiety, addictive, and sleep disorders in older patients, as well as tested diagnostic tools and therapies.